Your browser doesn't support javascript.
loading
Tackling challenges in rare diseases: The ISGACA approach on non-pancreatic cancers in the periampullary region.
Uijterwijk, Bas A; Lemmers, Daniël H; Moekotte, Alma L; Zaniboni, Alberto; Ghidini, Michele; Wilmink, Hanneke; Milella, Michele; Scarpa, Aldo; Luchini, Claudio; Baboeram, Nigel; Klei, Dorine S; Manzoni, Alberto; Bannone, Elisa; Oneda, Ester; Besselink, Marc G; Abu Hilal, Mohammed.
Afiliación
  • Uijterwijk BA; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Lemmers DH; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Moekotte AL; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Zaniboni A; Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy.
  • Ghidini M; Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Wilmink H; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, the Netherlands.
  • Milella M; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University and Hospital Trust (AOUI), Verona, Italy.
  • Scarpa A; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
  • Luchini C; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
  • Baboeram N; Department of Surgery, Fondazione Poliambulanza, Brescia, Italy; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Klei DS; Department of Surgery, Fondazione Poliambulanza, Brescia, Italy.
  • Manzoni A; Department of Surgery, Fondazione Poliambulanza, Brescia, Italy.
  • Bannone E; Department of Surgery, Fondazione Poliambulanza, Brescia, Italy.
  • Oneda E; Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy.
  • Besselink MG; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Abu Hilal M; Department of Surgery, Fondazione Poliambulanza, Brescia, Italy; Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. Electronic address: abuhilal9@gmail.com.
Eur J Surg Oncol ; 50(11): 108601, 2024 Aug 13.
Article en En | MEDLINE | ID: mdl-39182309
ABSTRACT

OBJECTIVE:

Rare but aggressive cancer types like non-pancreatic periampullary cancers pose unique challenges for cancer research due to their low incidence rates and lack of consensus on optimal treatment strategies, therefore necessitating a collaborative approach. The International Study Group on non-pancreatic peri-Ampullary CAncer (ISGACA) aimed to build a collaborative initiative to pool expertise, funding opportunities, and data from over 60 medical centers, in order to improve outcomes for underrepresented patients with rare cancers.

METHODS:

The ISGACA approach predefined a stepwise approach including a research scope, establishing a dedicated steering committee, creating a recognizable brand, identifying research gaps, following a well-defined timeline, ensuring robust data collection, addressing legal and ethical considerations, securing financial resources, investing in research ethics training and statistical expertise, raising awareness, creating uniformity, and initiating prospective studies.

RESULTS:

Overall, 60 medical centers joined the ISGACA consortium (41 in Europe, 15 in North-America, three in Asia, one in Australia). The database includes 4309 patients. Nine publications and several ongoing studies which in turn allowed for a successful application of research grants. Subsequently, an international consensus meeting established uniform definitions and classifications, and one prospective multicenter international clinical trial has been initiated.

CONCLUSION:

By sharing knowledge, expertise, and clinical data, the ISGACA approach has not only gathered sufficient evidence to secure grants and ethical approvals for prospective studies, but also demonstrates options for standardizing patient care and improving outcomes for patients with rare cancers. The ISGACA approach offers a detailed methodology for initiating research on rare cancers and could serve as a replicable model for future research initiatives.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido